About this sleep apnea research news STUDY OBJECTIVES: CLINICAL TRIAL REGISTRATION: Summary: Reboxetine, a selective norepinephrine reuptake inhibitor normally prescribed for depression, can reduce sleep apnea symptom severity. Source: Flinders University Targeting a condition suffered by nearly a billion people worldwide, a new study from Flinders University has shown ...
View more: Promising Medication for Sleep Apnea